For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

Managing pyrexia

Pyrexia may be managed with dose interruption or antipyretic treatment, which generally can allow treatment to resume.1,2

Steps for managing pyrexia (≥38.5°C)1,2

Manage pyrexia in 3 steps—interrupt, manage, and consider.

For patients with BRAF V600+ unresectable or metastatic melanoma3,4:

  • Pyrexia was the most common adverse reaction with Tafinlar + Mekinist (52%-57% overall, 5%-7% grade 3)
  • Tafinlar + Mekinist discontinuation rate due to pyrexia was 2% to 5% across the phase 3 studies

For patients with BRAF V600+ NSCLC5:

  • Pyrexia was one of the most common adverse reactions, reported by 55% of patients receiving Tafinlar + Mekinist

  • 2 patients discontinued Tafinlar + Mekinist due to pyrexia

References: 1Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017. 2Mekinist Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017. 3. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.Lancet. 2015;386(9992):444-451. 4Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib + trametinib in patients with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. Presented at: European Society for Medical Oncology; October 7-11, 2016; Copenhagen, Denmark. 5. Tafinlar [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2017.